Drug intelligence / Profile preview

AYUB15 + NS14

Development stage: Preclinical
Lead developer: AYUB R&D

Overview

AYUB15 + NS14 is a preclinical-stage combination of plant-derived essential oils being developed by AYUB R&D for the treatment of bladder cancer. The formulation consists of an enriched Boswellia sacra (frankincense) essential oil extract, designated as AYUB15, and a Nigella sativa (black seed) essential oil extract, designated as NS14. Preclinical research using the J82 bladder cancer cell line has demonstrated synergistic anticancer activity from the combination. Although the individual components contain bioactive compounds such as boswellic acids and thymoquinone, no specific molecular target has been formally identified for this combination; its efficacy is currently attributed to the combined pharmacological properties of the two essential oils.

Other names: Boswellia sacra and Nigella sativa essential oil combination

Beyond the preview

Go deeper on AYUB15 + NS14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYUB15 + NS14.

Explore the full profile